Last updated: October 5, 2026
Canagliflozin is a mature SGLT2 inhibitor marketed primarily as Invokana, Invokamet, and Invokamet XR. Its commercial position weakened after cardiovascular and amputation safety concerns and stronger competition from empagliflozin and dapagliflozin. The drug regained clinical relevance through renal and cardiovascular outcome data, particularly the CREDENCE trial, but its US growth has remained limited.
The primary US composition patent expired in late 2024, ending the principal period of small-molecule exclusivity. Remaining formulation and method-of-use patents may delay or narrow generic competition, but they are less likely to preserve branded pricing once an authorized or fully substitutable generic enters the market.
What is the current market position of canagliflozin?
Canagliflozin is an oral sodium-glucose cotransporter-2 inhibitor that reduces renal glucose reabsorption. Johnson & Johnson commercialized the product through Janssen under the Invokana brand. Mitsubishi Tanabe Pharma discovered canagliflozin and partnered with Janssen for development and commercialization.
The principal products are:
| Product |
Active ingredient |
Dosage form |
Primary use |
| Invokana |
Canagliflozin |
Immediate-release tablets |
Type 2 diabetes, diabetic kidney disease, cardiovascular risk reduction |
| Invokamet |
Canagliflozin/metformin |
Immediate-release tablets |
Type 2 diabetes |
| Invokamet XR |
Canagliflozin/metformin extended release |
Extended-release tablets |
Type 2 diabetes |
The FDA originally approved Invokana in March 2013 for glycemic control in adults with type 2 diabetes. The agency later expanded the product’s clinical positioning based on cardiovascular and renal outcomes. In 2019, FDA labeling incorporated data from CREDENCE, which showed reduced risk of kidney failure and cardiovascular events in patients with type 2 diabetes and diabetic kidney disease treated with canagliflozin.[1]
Canagliflozin competes principally with:
- Jardiance, empagliflozin, marketed by Boehringer Ingelheim and Eli Lilly.
- Farxiga, dapagliflozin, marketed by AstraZeneca.
- Steglatro, ertugliflozin, marketed by Merck and Pfizer.
- Generic and branded versions of other glucose-lowering therapies, including GLP-1 receptor agonists and DPP-4 inhibitors.
Empagliflozin and dapagliflozin have achieved stronger commercial momentum because of broad cardiovascular, heart-failure, and chronic-kidney-disease positioning. Canagliflozin retains differentiated renal-outcome data but has a smaller commercial platform.
How has canagliflozin revenue changed over time?
Janssen’s Invokana franchise expanded rapidly after launch, then plateaued following safety concerns, competitive pressure, and changes in prescribing behavior.
Approximate worldwide sales reported by Johnson & Johnson are shown below. Figures reflect the Invokana franchise and may include related formulations depending on the reporting year.
| Year |
Approximate sales |
Commercial development |
| 2013 |
$0.03 billion |
US launch year |
| 2014 |
$0.58 billion |
Rapid early adoption |
| 2015 |
$1.03 billion |
Peak growth phase |
| 2016 |
$1.41 billion |
Pre-safety-signal peak |
| 2017 |
$1.04 billion |
Decline after safety concerns |
| 2018 |
$1.13 billion |
Stabilization |
| 2019 |
$1.11 billion |
CREDENCE-supported recovery |
| 2020 |
$1.05 billion |
Mature franchise |
| 2021 |
Approximately $1.0 billion |
Stable but competitive market |
| 2022 |
Approximately $1.0 billion |
Limited growth |
| 2023 |
Approximately $1.0 billion |
Mature branded product |
Johnson & Johnson’s annual reports identify Invokana as a material but declining or mature pharmaceutical franchise compared with newer products such as Stelara, Darzalex, Erleada, and Tremfya.[2]
The financial trajectory has four stages:
Launch and rapid uptake
Invokana benefited from being among the first widely commercialized SGLT2 inhibitors in the United States. The drug offered oral dosing, weight-loss potential, and blood-pressure benefits compared with several older diabetes treatments.
Safety-driven contraction
In 2015, FDA added warnings relating to ketoacidosis, kidney injury, and other risks. The CANVAS Program later reported an increased risk of lower-limb amputation with canagliflozin, which affected prescribing and payer perception.[3]
Evidence-supported stabilization
The CREDENCE trial demonstrated substantial renal benefits in patients with type 2 diabetes and chronic kidney disease. The results helped reposition Invokana from a glucose-lowering product toward a cardiorenal-risk-reduction therapy.[4]
Patent-driven erosion
The expiry of the principal composition patent removes a major barrier to generic entry. Branded sales are likely to decline sharply once a generic reaches meaningful pharmacy substitution and payer coverage.
When does canagliflozin lose US exclusivity?
Canagliflozin’s five-year new chemical entity exclusivity expired in 2018. Pediatric exclusivity may have extended certain protections by six months, but it did not create a long-term commercial barrier.
The key US composition patent, commonly identified as US Patent No. 6,414,126, covered C-glucoside derivatives including canagliflozin. Its effective expiration date was in late 2024 after applicable patent-term adjustments.[5]
| Exclusivity or patent right |
Approximate status |
| FDA new chemical entity exclusivity |
Expired in 2018 |
| Pediatric exclusivity |
Expired after the applicable six-month extension |
| Core composition patent, US 6,414,126 |
Expired in late 2024 |
| Formulation patents |
Some rights may extend beyond the composition patent |
| Method-of-use patents |
Potentially relevant to specific indications and labeling |
| Regulatory orphan exclusivity |
Not a principal protection for Invokana |
The practical commercial date is not determined solely by the composition patent. Generic applicants may challenge listed patents before expiry, and FDA approval may occur after litigation, settlement, or expiration of the relevant patent claims.
What patents protect Invokana and canagliflozin?
The canagliflozin patent estate has historically included four categories:
- Composition-of-matter patents covering the active molecule and related C-glucoside compounds.
- Crystalline-form or solid-state patents.
- Tablet and combination-product patents.
- Method-of-use patents covering treatment of diabetes, diabetic nephropathy, cardiovascular risk, or related conditions.
The core composition patent created the strongest barrier because a generic applicant could not avoid infringing it by changing excipients or tablet design. After its expiration, remaining patents become more important but generally have narrower scope.
Formulation patents
Formulation protection covers tablet compositions, release characteristics, combinations with metformin, and manufacturing specifications. Invokamet and Invokamet XR may have patent claims distinct from those covering Invokana alone.
Formulation patents can delay a generic version of a specific product, but they do not necessarily block all canagliflozin tablets. A generic applicant may design around a formulation claim or seek approval for a different dosage form.
Method-of-use patents
Method-of-use patents can cover treatment of diabetic kidney disease, reduction of cardiovascular risk, or use in particular patient populations. Their commercial value depends on:
- Whether the indication is carved out of the generic label.
- Whether prescribers use the drug for the patented indication.
- Whether payers and pharmacies substitute the generic automatically.
- Whether induced-infringement claims can be supported.
Skinny-label strategies can reduce a generic applicant’s exposure to method-of-use claims, although they do not eliminate litigation risk.
What is the Orange Book status of Invokana?
The FDA Orange Book lists patents submitted by the innovator for approved drug products. These listings determine the patent certifications required of abbreviated new drug application applicants.
A generic applicant generally must certify that:
- No relevant patent is listed.
- The listed patent has expired.
- The applicant will not market before patent expiration.
- The patent is invalid, unenforceable, or will not be infringed under a Paragraph IV certification.
A Paragraph IV certification can trigger patent litigation and a potential 30-month stay of FDA approval under the Hatch-Waxman Act. The stay applies only when the innovator files an infringement action within the statutory period.[6]
For canagliflozin, the commercial importance of Orange Book listings has shifted since the expiration of the core composition patent. The remaining issues concern formulation, combination products, and indication-specific claims rather than basic access to the molecule.
Which companies have challenged canagliflozin patents?
Publicly reported generic activity has involved major ANDA manufacturers seeking approval for canagliflozin tablets and canagliflozin/metformin products. The relevant competitive group has included companies such as Lupin, Zydus, Alembic, Mylan or Viatris, and other large Indian and US generic manufacturers.
The litigation pattern has generally followed the standard Hatch-Waxman sequence:
- ANDA submission with a Paragraph IV certification.
- Janssen patent-infringement complaint.
- A statutory stay of FDA approval.
- Settlement, judgment, or patent expiry.
- Potential launch after approval and resolution of the listed patent barrier.
The core composition patent’s late-2024 expiration materially reduces the litigation leverage available to Janssen. Any continuing cases are more likely to involve individual products, formulation claims, or launch timing rather than a complete exclusion of all generic canagliflozin.
How strong is the canagliflozin patent estate?
The estate was strong during the composition-patent period and is materially weaker after late 2024.
| Patent category |
Historical strength |
Post-composition-expiry strength |
| Core molecule |
Very strong |
Expired |
| Crystalline form |
Moderate to strong |
Product-specific |
| Invokana tablet formulation |
Moderate |
Potentially relevant |
| Invokamet combination |
Moderate |
Relevant to combination products |
| Invokamet XR |
Moderate |
Relevant if claims remain enforceable |
| Cardiovascular or renal use |
Moderate |
Dependent on label and infringement facts |
| Manufacturing process |
Variable |
Relevant mainly to supply and process control |
The estate can still support litigation against a particular generic product. It is less likely to preserve the overall Invokana franchise because generic applicants can target the active ingredient with noninfringing formulations and omit protected indications where permitted.
What generic entry risks exist for canagliflozin?
The generic-entry risk is high in the United States after expiry of the core composition patent.
Base-case scenario
The most likely path is staged generic entry:
- Initial FDA approvals for canagliflozin tablets.
- Limited launch by one or more first entrants.
- Price discounts below the branded product.
- Rapid payer conversion once supply becomes reliable.
- Progressive decline in Invokana and Invokamet volume.
Accelerated erosion scenario
If several generic manufacturers launch near the same date, net prices could fall quickly. Pharmacy-benefit managers may place generic canagliflozin on preferred tiers, reducing branded utilization even if Janssen offers rebates.
Delayed-erosion scenario
Branded sales could persist if:
- Generic approvals remain tied up in product-specific litigation.
- Manufacturers face supply or manufacturing constraints.
- Payers preserve coverage for renal specialists.
- The branded product retains preferred status for patients already stabilized on therapy.
The most exposed revenue is US diabetes revenue. Renal and cardiovascular use supports clinical demand but does not prevent generic substitution once the same active ingredient is available.
How does canagliflozin compare with Jardiance and Farxiga?
| Factor |
Invokana |
Jardiance |
Farxiga |
| Active ingredient |
Canagliflozin |
Empagliflozin |
Dapagliflozin |
| Initial FDA approval |
2013 |
2014 |
2014 |
| Key differentiation |
CREDENCE renal data |
EMPA-REG cardiovascular data |
Heart failure and CKD data |
| Historical safety issue |
Amputation signal, later boxed warning removed |
Genital infections, ketoacidosis class risks |
Genital infections, ketoacidosis class risks |
| Commercial position |
Mature, declining |
Leading franchise |
Leading growth platform |
| Patent exposure |
Core patent expired in 2024 |
Later patent barriers |
Later patent barriers |
| Main strategic risk |
Generic erosion and share loss |
Future loss of exclusivity |
Future loss of exclusivity |
FDA removed the boxed warning regarding amputation risk from Invokana in 2020 after reviewing new data, while maintaining information about the risk in the prescribing information.[7] The removal improved the product’s regulatory profile but did not reverse the market-share advantage held by Jardiance and Farxiga.
What FDA regulatory status does canagliflozin have?
Invokana remains FDA-approved for adult patients with type 2 diabetes as an adjunct to diet and exercise. Its label also includes reduction of the risk of end-stage kidney disease, worsening kidney function, cardiovascular death, and hospitalization for heart failure in specified patients with type 2 diabetes and diabetic kidney disease.[8]
The regulatory profile is commercially important because the renal indication can support continued use by nephrologists and endocrinologists. It also creates method-of-use patent considerations for generic applicants.
Canagliflozin is not a biologic, so biosimilar substitution is not relevant. Its competitive threat comes from conventional ANDA generics rather than biosimilars.
What licensing deals support canagliflozin commercialization?
Mitsubishi Tanabe Pharma developed canagliflozin and entered into an agreement with Janssen for development and commercialization. Janssen led major global commercialization activities, while Mitsubishi Tanabe retained rights or commercial participation in selected markets under the parties’ arrangements.
The partnership created a global commercial platform but also divided economics between the originator and license partners. As patent protection expires, the value of the arrangement shifts from exclusivity rents toward residual branded demand, supply relationships, and geographic rights.
What manufacturing and geographic barriers remain?
Canagliflozin is a chemically synthesized small molecule with no biologic manufacturing barrier. Generic manufacturers can produce the active ingredient and finished tablets using established oral-solid-dose technology.
Remaining barriers include:
- Active pharmaceutical ingredient qualification.
- Demonstration of bioequivalence.
- Control of polymorphic or crystalline forms.
- Tablet manufacturing scale.
- Regulatory approval in each jurisdiction.
- Local patent and data-exclusivity rules.
- Distribution and payer contracting.
The US is the most economically important market for Invokana. Generic-entry timing in Europe, Japan, Canada, China, India, and other markets depends on local patent terms and regulatory pathways. A US patent expiry does not automatically authorize global generic sales.
What is the investment outlook for canagliflozin?
Canagliflozin is best viewed as a cash-generating mature asset rather than a growth product.
The principal financial drivers are:
- US generic-entry timing.
- The number of approved generic competitors.
- Branded rebate requirements.
- Continued renal-disease utilization.
- International patent and regulatory status.
- Janssen’s ability to retain patients with differentiated renal labeling.
Revenue risk is concentrated in the US. A generic launch could reduce branded net sales through both volume loss and price concessions. The renal indication may preserve a higher-value patient segment, but pharmacies and payers generally treat an approved generic with the same active ingredient as substitutable.
The asset retains scientific value because SGLT2 inhibitors remain central to diabetes, heart-failure, and chronic-kidney-disease treatment. That market growth benefits the drug class more than it benefits canagliflozin specifically. Jardiance and Farxiga are better positioned to capture new prescriptions while Invokana faces an approaching or completed loss of molecule-level exclusivity.
Key Takeaways
- Canagliflozin is marketed as Invokana, Invokamet, and Invokamet XR.
- Invokana sales peaked at roughly $1.4 billion in 2016 and stabilized near $1 billion annually in later years.
- The principal US composition patent, US 6,414,126, expired in late 2024.
- FDA new chemical entity exclusivity expired in 2018.
- Remaining formulation and method-of-use patents may affect individual generic products but are unlikely to preserve the full franchise.
- Generic-entry risk in the United States is high.
- CREDENCE strengthened the renal profile, but Jardiance and Farxiga have stronger commercial momentum.
- Biosimilar risk is irrelevant because canagliflozin is a small molecule.
- The principal investment risk is rapid US branded-sales erosion after generic approval and substitution.
- Canagliflozin remains clinically relevant, but its financial profile is that of a mature, patent-expired or near-patent-expired product.
FAQs
Is canagliflozin still patent protected in the United States?
The principal composition patent expired in late 2024. Product-specific formulation or method-of-use patents may remain relevant for particular Invokana or Invokamet products.
Does canagliflozin have a generic equivalent?
Generic approval and commercial availability depend on FDA approvals, Paragraph IV litigation, settlements, and individual product patents. The expiration of the core composition patent creates a substantially stronger basis for generic entry.
Why did Invokana sales decline after 2016?
Sales were affected by the CANVAS amputation signal, other safety concerns, increased competition from Jardiance and Farxiga, and changes in physician and payer preferences.
Is canagliflozin better than empagliflozin for kidney disease?
Both drugs have renal benefits, but clinical selection depends on the patient’s indication, kidney function, cardiovascular risk, label parameters, and payer coverage. CREDENCE provides particularly important evidence for canagliflozin in diabetic kidney disease.
Who owns the canagliflozin brand?
Janssen, part of Johnson & Johnson, commercializes Invokana in major markets under arrangements originating from Mitsubishi Tanabe Pharma’s development and licensing activities.
References
- U.S. Food and Drug Administration. (2019). FDA approves canagliflozin to reduce the risk of heart attack, stroke, and death in adults with type 2 diabetes.
- Johnson & Johnson. (2014-2023). Annual reports and Form 10-K filings.
- Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine, 377(7), 644-657.
- Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., et al. (2019). Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England Journal of Medicine, 380(24), 2295-2306.
- U.S. Patent No. 6,414,126. (2002). C-glucoside derivatives. United States Patent and Trademark Office.
- U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Food and Drug Administration. (2020). FDA removes boxed warning about risk of leg and foot amputations for diabetes medicine canagliflozin.
- Janssen Pharmaceuticals, Inc. (2024). Invokana prescribing information.
